Cellectis presents preclinical data highlighting effective APOC3 editing and marked triglyceride reduction with. HEAL-101 at ESGCT 2026.
Cellectis presents preclinical data highlighting effective APOC3 editing and marked triglyceride reduction with. HEAL-101 at ESGCT 2026.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in